Austin Blake Gardner

Austin Blake Gardner

Auto-generated profile, based on publicly available information

Austin Blake Gardner

Palo Alto Medical Foundation Research Institute, Palo Alto, CA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AGAustin B. Gardner
Austin B. Gardner
SLSimon K. C. Lee
Simon K. C. Lee
EWElliot C. Woods
Elliot C. Woods
AAAbhinav P. Acharya
Abhinav P. Acharya
The immune system is traditionally considered from the perspective of defending against bacterial or viral infections. However, foreign materials like implants can also illicit immune responses. These immune responses are mediated by a large number of molecular signals, including cytokines, antibodies and reactive radical species, and cell types, including macrophages, neutrophils, natural killer cells, T-cells, B-cells, and dendritic cells. Most often, these molecular signals lead to the generation of fibrous encapsulation of the biomaterials, thereby shielding the body from these biomaterials. In this review we will focus on two different types of biomaterials: those that actively modulate the immune response, as seen in antigen delivery vehicles for vaccines, and those that illicit relatively small immune response, which are important for implantable materials. The first serves to actively influence the immune response by co-opting certain immune pathways, while the second tries to mimic the properties of the host in an attempt to remain undetected by the immune system. As these are two very different end points, each type of biomaterial has been studied and developed separately and in recent years, many advances have been made in each respective area, which will be highlighted in this review.

1 January 2022 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
AGAustin B. Gardner
Austin B. Gardner
MCMacie L. Champion
Macie L. Champion
ABAshley Battarbee
Ashley Battarbee

1 August 2016 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
JCJohn K. Chan
John K. Chan
AGAustin B. Gardner
Austin B. Gardner
CLCheng-I Liao
Cheng-I Liao
JCJoshua Chan
Joshua Chan
AGAndrew Guan
Andrew Guan
DKDaniel S. Kapp
Daniel S. Kapp

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
IAIdoroenyi Amanam
Idoroenyi Amanam
AGAustin Blake Gardner
Austin Blake Gardner
NYNichole Young-Lin
Nichole Young-Lin
JCJohn K. Chan
John K. Chan
E14111 Background: In 2015, The FDA approved the most number of novel drugs in the last 19-years. We propose to evaluate the factors associated with the significant increase in FDA approved oncologic drugs over the last 5 years. Methods: Data was extracted from all novel drug license applications to the FDA. SAS was used to conduct Chi-squared tests. Results: The FDA approved 47 novel cancer drugs from 2011 to 2015, of which, 34 (72.3%) were new drug applications and 13 (27.7%) were biologic license applications. Of these, 35 (64.5%) were orphan and 19 (40.4%) were first-in-class drugs. Based on expedited approval, 36 (76.6%) underwent priority review, 27 (57.5%) fast track, 17 (36.2%) accelerated, and 11 (23.4%) had breakthrough designation. 31 (66%) were for solid and 16 (34%) for liquid cancers. 20 (42.6%) drugs were approved based on clinical response, 16 (34.0%) on progression-free survival and 11 (23.4%) on overall survival as primary endpoints. The median time from initiation of clinical trial to approval was 42 months (range: 17 to 78 months). Trials completed within a shorter time ( < 42 months, median) were more likely to receive fast track designation compared to those requiring a longer time (36.2% vs. 21.3%; p = 0.03). We divided the 5-year study over 3 time periods from Jan 2011 - Aug 2012, Sept 2012 - April 2014, and May 2014 - Dec 2015. 13 (27.7%), 15 (31.9%), and 19 (40.4%) drugs were approved in those periods, respectively. Over time, there was a trend towards an increase in orphan-designated drugs from 14.9%, to 25.5%, to 34.0% (p = 0.13). The proportion of accelerated drugs increased from 15.4%, to 33.3%, to 52.6% over the study period, though not statistically significant (p = 0.09). There was also no change with respect to application type, phase of clinical trial, and type of trial endpoint over time. Conclusions: The majority (65%) of new cancer drugs were approved under the orphan drug designation which has increased over the past 5 years. The median time from clinical trial initiation to FDA approval was 42 months. The increasing trend for novel drug approvals through these expedited programs based on shorter and smaller clinical trials warrants further investigation.

1 December 2015 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
JCJohn K. Chan
John K. Chan
AGAustin B. Gardner
Austin B. Gardner
CTCaroline A Thompson
Caroline A Thompson
DKDaniel S. Kapp
Daniel S. Kapp